Birmingham, Alabama Clinical Trials

A listing of Birmingham, Alabama clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

cns tumor
chemotherapeutic agents
cancer treatment
nervous system disorder
recurrent hepatoblastoma
Children's Hospital of Alabama
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

cataract
crizotinib
nf2 gene
schwartz
multiple meningiomas
The University of Alabama at Birmingham (Site 700)
 (1.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
A Study of CC-98633 BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to …

refractory multiple myeloma
carfilzomib
lenalidomide
bortezomib
pomalidomide
University of Alabama at Birmingham Hospital
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +8 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

datscan
alpha-synuclein
muscle rigidity
methyldopa
genetic testing
University of Alabama at Birmingham
 (1.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

imiglucerase
gaucher disease
deficiency
eliglustat
Investigational Site Number 840018
 (1.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

deficiency
gaa gene
replacement therapy
glycogen storage disease type ii
myozyme
Investigational Site Number 840106
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

deficiency
alpha-galactosidase
fabrazyme
agalsidase beta
replacement therapy
Investigational Site Number 840018
 (1.0 away) Contact site
  • 0 views
  • 05 Aug, 2024
  • +136 other locations
Micra AV Transcatheter Pacing System Post-Approval Registry

Medtronic is sponsoring the Micra AV Registry using the Micra AV system for continued surveillance of chronic atrioventricular synchronous pacing as intended, through the collection of data based on routine clinical care practice, following commercial release. The Micra AV Registry is conducted within Medtronic's Product Surveillance Registry (PSR) platform.

The University of Alabama at Birmingham
 (1.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Pediatric KIDney Stone (PKIDS) Care Improvement Network

The goals of this study are to improve the ability of pediatric patients and their caregivers to select surgical treatment options for kidney stones and to enable urologists to use techniques that result in the best outcomes for these surgeries.

nephrolithotomy
lithotripsy
shock
ureterolithiasis
nephrolithiasis
Children's of Alabama
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
NCI COVID-19 in Cancer Patients NCCAPS Study

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects …

solid tumor
cancer treatment
rituximab
mek inhibitor
nucleic acid
University of Alabama at Birmingham Cancer Center
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +575 other locations